NCCN now recognizes personalized, tumor-informed ctDNA-MRD as a prognostic and predictive biomarker in MIBC, extending ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the National Comprehensive Cancer Network® (NCCN®) has updated its Clinical Practice ...

Tiny algae-based robots guided by magnets could improve bladder cancer treatment by boosting delivery of chemotherapy drugs ...

Tiny algae-based robots guided by magnets could improve bladder cancer treatment by boosting delivery of chemotherapy drugs ...

The guidelines state that a test must be FDA-approved, personalized, tumor-informed, multiplex, and use PCR-NGS for ctDNA.

Researchers at The University of Texas MD Anderson Cancer Center have developed a spatial map of muscle-invasive bladder ...

Although bladder cancer ranks as the sixth most common cancer in the United States, with approximately 85,000 new cases diagnosed each year, it continues to receive limited awareness, advocacy, and ...

The US Food and Drug Administration has approved Johnson & Johnson’s drug delivery system for a type of bladder cancer, offering a potential surgery-free option for patients. The drug release system, ...

A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with high-risk non-muscle-invasive bladder cancer whose cancer had previously ...

Bladder cancer is a common cancer and one of the most costly to treat, yet there has been little change in the standard of care in 40 years. This panel will focus on the unmet needs in bladder cancer ...

Bladder cancer frequently announces itself through symptoms that patients dismiss as minor urinary issues, and that delay between first sign and diagnosis can mean the difference between a ...